Phase 1 study of dry eye solution launched

Article

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

Novaliq GmbH is launching a Phase 1 study of its 0.05% clear cyclosporine solution (CyclASol) following European and US patent approval of the solution for the treatment of dry eye syndrome.

CyclASol was developed from EyeSol, Novaliq's broad range semi-fluorinated alkane (SFA) drug delivery platform. Novaliq says the platform offers significant benefits for delivery of ophthalmological drugs, primarily by enhancing the therapeutic effect of poorly soluble drugs.

According to Novaliq, CyclASol has demonstrated long-term stability and wettability, pharmacokinetics, and biocompatibility superior to that of conventional emulsion formulations of cyclosporine. CyclASol is available in multidose and preservative-free bottles.

"We are pleased to receive the US and European patent and to announce the start of a Phase 1 CyclASol study," Bernhard Günther, CEO of Novaliq GmbH, said. "These are both significant new milestones for Novaliq as we build our innovative drug delivery portfolio."

"We congratulate Novaliq on obtaining patent approval for CyclASol and the start of their clinical trials," said Mathias Hothum, managing director of investment company Dievini Hopp BioTech Holding GmbH & Co. KG. "We are pleased to support Novaliq as it pioneers new topical ocular drug delivery technology. We endorse Novaliq's strategy to establish a portfolio of consumer and prescription product portfolios within ophthalmology."

For more information, visit www.novaliq.de or e-mail: info@novaliq.de.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.